Primary sclerosing cholangitis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) |
|||
| Line 13: | Line 13: | ||
*** The ''American College of Gastroenterology,'' 2015 guidelines does not support the use of [[ursodeoxycholic acid]] in patients with primary sclerosing cholangitis.<ref name="pmid20101749">{{cite journal |vauthors=Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ |title=Diagnosis and management of primary sclerosing cholangitis |journal=Hepatology |volume=51 |issue=2 |pages=660–78 |year=2010 |pmid=20101749 |doi=10.1002/hep.23294 |url=}}</ref><ref name="pmid19501929">{{cite journal |vauthors= |title=EASL Clinical Practice Guidelines: management of cholestatic liver diseases |journal=J. Hepatol. |volume=51 |issue=2 |pages=237–67 |year=2009 |pmid=19501929 |doi=10.1016/j.jhep.2009.04.009 |url=}}</ref><ref name="pmid25869391">{{cite journal |vauthors=Lindor KD, Kowdley KV, Harrison ME |title=ACG Clinical Guideline: Primary Sclerosing Cholangitis |journal=Am. J. Gastroenterol. |volume=110 |issue=5 |pages=646–59; quiz 660 |year=2015 |pmid=25869391 |doi=10.1038/ajg.2015.112 |url=}}</ref> | *** The ''American College of Gastroenterology,'' 2015 guidelines does not support the use of [[ursodeoxycholic acid]] in patients with primary sclerosing cholangitis.<ref name="pmid20101749">{{cite journal |vauthors=Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ |title=Diagnosis and management of primary sclerosing cholangitis |journal=Hepatology |volume=51 |issue=2 |pages=660–78 |year=2010 |pmid=20101749 |doi=10.1002/hep.23294 |url=}}</ref><ref name="pmid19501929">{{cite journal |vauthors= |title=EASL Clinical Practice Guidelines: management of cholestatic liver diseases |journal=J. Hepatol. |volume=51 |issue=2 |pages=237–67 |year=2009 |pmid=19501929 |doi=10.1016/j.jhep.2009.04.009 |url=}}</ref><ref name="pmid25869391">{{cite journal |vauthors=Lindor KD, Kowdley KV, Harrison ME |title=ACG Clinical Guideline: Primary Sclerosing Cholangitis |journal=Am. J. Gastroenterol. |volume=110 |issue=5 |pages=646–59; quiz 660 |year=2015 |pmid=25869391 |doi=10.1038/ajg.2015.112 |url=}}</ref> | ||
*** The ''American Association for the Study of Liver Diseases,'' 2010 guidelines recommends ''against'' the use of [[ursodeoxycholic acid]] in the treatment of primary sclerosing cholangitis. | *** The ''American Association for the Study of Liver Diseases,'' 2010 guidelines recommends ''against'' the use of [[ursodeoxycholic acid]] in the treatment of primary sclerosing cholangitis. | ||
* Associated medical conditions and manifestations of [[end | * Associated medical conditions and manifestations of [[End stage liver failure|end stage liver disease]] ([[End stage liver failure|ESLD]]) can be targeted by medical therapy and/or surgery. | ||
==References== | ==References== | ||
Latest revision as of 16:50, 6 December 2017
|
Primary sclerosing cholangitis Microchapters |
|
Differentiating Primary sclerosing cholangitis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary sclerosing cholangitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Primary sclerosing cholangitis medical therapy |
|
Directions to Hospitals Treating Primary sclerosing cholangitis |
|
Risk calculators and risk factors for Primary sclerosing cholangitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]
Overview
Liver transplantation is the gold standard for treatment of primary sclerosing cholangitis and there is no effective medical treatment. Ursodeoxycholic acid has been studied as a treatment for the disease. However, there is no proof for its benefit and the American College of Gastroenterology does not support its use in patients with primary sclerosing cholangitis.
Medical Therapy
- Liver transplantation is the gold standard for treatment of primary sclerosing cholangitis and there is no effective medical treatment.
- Ursodeoxycholic acid (UDCA) in the dose of 10-15 mg/kg/day has been studied as a treatment for the disease.
- However, there is no proof for the use of ursodeoxycholic acid in patients with primary sclerosing cholangitis.[1]
- The American College of Gastroenterology, 2015 guidelines does not support the use of ursodeoxycholic acid in patients with primary sclerosing cholangitis.[2][3][4]
- The American Association for the Study of Liver Diseases, 2010 guidelines recommends against the use of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
- However, there is no proof for the use of ursodeoxycholic acid in patients with primary sclerosing cholangitis.[1]
- Associated medical conditions and manifestations of end stage liver disease (ESLD) can be targeted by medical therapy and/or surgery.
References
- ↑ Angulo P, Lindor KD (1999). "Primary biliary cirrhosis and primary sclerosing cholangitis". Clin Liver Dis. 3 (3): 529–70. PMID 11291238.
- ↑ Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010). "Diagnosis and management of primary sclerosing cholangitis". Hepatology. 51 (2): 660–78. doi:10.1002/hep.23294. PMID 20101749.
- ↑ "EASL Clinical Practice Guidelines: management of cholestatic liver diseases". J. Hepatol. 51 (2): 237–67. 2009. doi:10.1016/j.jhep.2009.04.009. PMID 19501929.
- ↑ Lindor KD, Kowdley KV, Harrison ME (2015). "ACG Clinical Guideline: Primary Sclerosing Cholangitis". Am. J. Gastroenterol. 110 (5): 646–59, quiz 660. doi:10.1038/ajg.2015.112. PMID 25869391.